|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases.
|
31345012 |
2020 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The EGFR T790M mutation in plasma cfDNA is a sensitive marker for EGFR TKI resistance when CNS metastases progressed.
|
31161597 |
2019 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Compared with chemotherapy, molecular testing in plasma and tissue followed by osimertinib treatment yielded an additional 0.359 and 0.313 QALYs in the entire U.S. population and the population of those with central nervous system metastases and an EGFR T790M mutation.
|
29101057 |
2018 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy.
|
27959700 |
2017 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib.
|
27177916 |
2016 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We analyzed DNA samples isolated from paraffin-embedded tissue from CNS metastases for T790M mutations using real-time PCR and TaqMan probe against the T790M mutant sequence.
|
24789720 |
2014 |
|
rs104893877
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gastrointestinal dysfunction in A53T αS mice represents an early sign of αS-driven pathology without concomitant CNS involvement.
|
30774946 |
2019 |
|
rs1057519847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
|
rs1057519848
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Vemurafenib as first-line therapy in <i>BRAF</i>-V600E-mutant Erdheim-Chester disease with CNS involvement.
|
31748352 |
2019 |
|
rs121434568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
|
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Vemurafenib as first-line therapy in <i>BRAF</i>-V600E-mutant Erdheim-Chester disease with CNS involvement.
|
31748352 |
2019 |
|
rs11686903
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate analysis showed associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903 and PI3KR1-rs706716 and CNS metastasis .
|
29103666 |
2017 |
|
rs3730050
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate analysis showed associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903 and PI3KR1-rs706716 and CNS metastasis .
|
29103666 |
2017 |
|
rs706716
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PI3KR1-rs706716 may be associated with CNS metastasis in metastatic breast cancer patients and could be included in a predictive composite score to detect early CNS metastasis irrespective of breast cancer subtype.
|
29103666 |
2017 |
|
rs1057519729
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using HRM and ASP-qPCR methods we identified one (0.7 %; 1/145) MEK1 substitution (Q56P) in CNS metastases of NSCLC.
|
26860843 |
2016 |
|
rs28933979
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
|
25091367 |
2015 |
|
rs267598140
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
|
25173530 |
2014 |
|
rs778199483
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
|
25173530 |
2014 |